Letters to the Editor
Meperidine to Manage Pain Related to Diverticular Disease
Am Fam Physician. 2006 Jun 15;73(12):2123.
To the editor: The article “Diverticular Disease: Diagnosis and Treatment”1 in the October 1, 2005, issue of American Family Physician recommended multiple times that patients needing narcotics for pain should be treated with meperidine (Demerol) rather than morphine. The two references used to support the claim do not appear to be relevant to the recommendation. In the past, meperidine has been claimed to be superior to morphine in patients with pancreatitis because of “sphincter of Oddi spasm”2 despite a complete absence of supporting outcome-based studies.3
Meperidine has a number of distinct disadvantages relative to other narcotic analgesics. Its analgesic effects are not pronounced, and its duration of action is short. It has multiple potential drug interactions, including the possibility of serotonergic crisis, and has toxic metabolites that may induce central nervous system dysfunction, including seizures.4 The unique disadvantages of meperidine have prompted some hospitals to ban its routine use.5
Proof of the alleged superiority of meperidine in the management of diverticular disease also appears to be lacking in outcome-based studies, whereas the hazards of meperidine use relative to other analgesics are well established. I would be interested in knowing if any evidence exists to support the implied claim that morphine worsens patient outcomes relative to meperidine.
1. Salzman H, Lillie D. Diverticular disease: diagnosis and treatment. Am Fam Physician. 2005;72:1229–34.
2. Munoz A, Katerndahl D. Diagnosis and management of acute pancreatitis. Am Fam Physician. 2000;62:164–74.
3. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi. Am J Gastroenterol. 2001;96:1266–72.
4. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther. 2002;9:53–68.
5. O’Connor AB, Lang VJ, Quill TE. Eliminating analgesic meperidine use with a supported formulary restriction. Am J Med. 2005;118:885–9.
in reply: I concur with Dr. Adams that there is a paucity of outcome-based research comparing meperidine (Demerol) head-to-head with morphine in the management of painful diverticular syndromes. Certainly, however, literature describes potential adverse effects of morphine on the colon. Studies performed on dogs,1 followed by subhuman primates,2 and finally in humans,3 demonstrate an increase in colonic tone and nonmigrating myoelectric spikes, with alteration of colonic motility.
It has long been generally accepted that meperidine causes less smooth muscle spasm and less constipation than morphine. As with much “conventional” clinical wisdom, there is no supporting evidence from randomized controlled trials. However, the existence of numerous case reports of morphine causing these problems, and no case reports regarding meperidine, does seem to lend this conventional wisdom some credence.
Meperidine should not be used in persons with a history of seizure disorders, nor in high doses or for prolonged periods, because accumulation of a toxic metabolite occurs and increases central nervous system excitability. As with all medications, one must be aware of drug interactions. Despite these limitations, I would continue to assert that meperidine has a place in the pain management of painful diverticular syndromes.
1. Neri M, Phillips SF, Fich A. Measurement of tone in the canine colon. Am J Physiol. 1991;260:G505–11.
2. Frantzides CT, Condon RE, Schulte WJ, Cowles V. Effects of morphine on colonic myoelectric and motor activity in subhuman primates. Am J Physiol. 1990;258:G247–52.
3. Frantzides CT, Cowles V, Salaymeh B, Tekin E, Condon RE. Morphine effects on human colonic myoelectric activity in the postoperative period. Am J Surg. 1992;163:144–8.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions